Drug Interaction Between CKD-501 and Metformin

Phase 1 Completed 24 enrolled Chong Kun Dang Pharmaceutical

RandomizedCrossoverOpen-label

Summary

The purpose of this study is to evaluate safety, tolerance by comparing availability and the pharmacokinetic drug interaction between the CKD-501 and metformin when administered alone and combination to healthy male volunteers.

Timeline

Start: 2009-10
Primary completion: 2009-12
Completion: 2010-02

Publications

Shin D, Kim TE, Yoon SH, Cho JY, Shin SG, Jang IJ, Yu KS. Assessment of the pharmacokinetics of co-administered metformin and lobeglitazone, a thiazolidinedione antihyperglycemic agent, in healthy subjects. Curr Med Res Opin. 2012 Jul;28(7):1213-20. doi: 10.1185/03007995.2012.703131. Epub 2012 Jul 2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lobeglitazone	Small molecule	0.5 mg	Oral
Subject	Metformin	Small molecule	1000 mg	Oral

Indications

No indication recorded.